Connect
MJA
MJA

Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

Peter S Hamblin, Rosemary Wong and Leon A Bach
Med J Aust 2021; 214 (2): . || doi: 10.5694/mja2.50898
Published online: 1 February 2021

In reply: We thank Meyer and colleagues for their interest in our article. The risk of sodium–glucose cotransporter type 2 (SGLT2) inhibitor‐associated diabetic ketoacidosis in acutely unwell patients and people using ketogenic diets is already outlined in our article and does not require further comment.1

  • Peter S Hamblin1,2
  • Rosemary Wong3
  • Leon A Bach4,5

  • 1 Western Health, Melbourne, VIC
  • 2 University of Melbourne, Melbourne, VIC
  • 3 Box Hill Hospital, Melbourne, VIC
  • 4 Alfred Hospital, Melbourne, VIC
  • 5 Monash University, Melbourne, VIC

Correspondence: peter.hamblin@wh.org.au

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.